Simulations Plus (NASDAQ:SLP – Get Free Report) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.07-$1.20 for the period, compared to the consensus earnings per share estimate of $1.01. The company issued revenue guidance of $90-$93 million, compared to the consensus revenue estimate of $90.71 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.
Simulations Plus Price Performance
Shares of SLP opened at $28.21 on Thursday. Simulations Plus has a one year low of $24.00 and a one year high of $51.22. The company has a 50-day moving average of $29.79 and a two-hundred day moving average of $34.00. The stock has a market cap of $566.60 million, a price-to-earnings ratio of 57.57 and a beta of 0.80.
Simulations Plus (NASDAQ:SLP – Get Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The firm had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $19.73 million. During the same period in the previous year, the company posted $0.18 EPS. The company’s quarterly revenue was up 19.9% compared to the same quarter last year. Analysts anticipate that Simulations Plus will post 1.1 earnings per share for the current year.
Analyst Ratings Changes
View Our Latest Stock Report on Simulations Plus
Insider Buying and Selling at Simulations Plus
In other news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $31.76, for a total value of $635,200.00. Following the sale, the director now owns 3,442,584 shares of the company’s stock, valued at approximately $109,336,467.84. This represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 19.40% of the company’s stock.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
See Also
- Five stocks we like better than Simulations Plus
- How to Calculate Stock Profit
- Discover 2 Under-the-Radar Aerospace Stocks Set for 2025 Growth
- Bank Stocks – Best Bank Stocks to Invest In
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- The Most Important Warren Buffett Stock for Investors: His Own
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.